From his perspective, one of the most persistent misconceptions in prostate cancer care relates to how patients interpret ...

New data show precision cancer testing still lags for Black, Hispanic, low-income and Medicare/Medicaid patients, delaying ...

Vir Biotechnology has dosed the first patient in one of three expansion cohorts in its ongoing Phase I clinical trial of VIR-5500 for metastatic prostate cancer.

Vir Biotechnology (VIR) has advanced its oncology program by dosing the first patient in a Phase 1 expansion cohort for VIR-5500 in metastatic prostate cancer, following encouraging early safety and ...

(HealthDay News) — For men with locally advanced prostate cancer, transdermal estradiol (tE2) patches are noninferior to luteinizing hormone-releasing hormone (LHRH) agonists as androgen deprivation ...

Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the use ...

Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall ...

PRO-XTEN dual masking aims to keep the engager inactive in circulation, activate within tumor protease-rich microenvironments ...

Prostate cancer is one of the most prevalent malignancies in men and remains a leading cause of cancer-related morbidity and mortality worldwide. For many, prostate cancer follows an indolent course, ...

The addition of the AKT inhibitor capivasertib (Truqap) to abiraterone (Zytiga) and androgen deprivation therapy (ADT) ...

Sonablate, a global leader in focused ultrasound technologies, today announced key additions to its leadership team as it scales "precision sound medicine"--using targeted ultrasound energy to treat ...

Northwestern Medicine scientists have discovered that a specific long non-coding RNA activates oncogenic signaling pathways ...